Analysed RAPPORT THERAPEUTICS INC (RAPP:NASDAQ) News Sources
This $64 Million Biotech Exit Seemingly Missed a 77% One-Day Surge on Gilead Takeover Deal
16-03-2026
fool.com
How Investors May Respond To Rapport Therapeutics (RAPP) Licensing RAP-219 To Tenacia In Greater China
21-03-2026
yahoo.com
All You Need to Know About Rapport Therapeutics, Inc. (RAPP) Rating Upgrade to Buy
26-03-2026
yahoo.com
Rapport Therapeutics to Present New Phase 2 Treatment Follow-Up Data for RAP-219 in Focal Onset Seizures at the 2026 American Academy of Neurology Annual Meeting
01-04-2026
yahoo.com
Rapport Therapeutics Presents RAP-219 Focal Onset Seizure Phase 2a Follow-up Period Results Demonstrating Sustained Seizure Reduction at the 2026 American Academy of Neurology Annual Meeting
21-04-2026
yahoo.com
Rapport Insider Sells $17.2 Million as Stock Surges 230% in a Year and Phase 3 Trials Near
27-04-2026
fool.com
Rapport Therapeutics Reports First Quarter 2026 Financials and Provides Business Update
07-05-2026
yahoo.com
What is the current price of RAPPORT THERAPEUTICS INC (RAPP:NASDAQ)?
The current price of RAPPORT THERAPEUTICS INC (RAPP:NASDAQ) is $39.51.
RAPPORT THERAPEUTICS INC (RAPP:NASDAQ) absolute price change since previous trading day?
The absolute price change of RAPPORT THERAPEUTICS INC (RAPP:NASDAQ) since the previous trading day is $-0.2.
RAPPORT THERAPEUTICS INC (RAPP:NASDAQ) percentage price change since previous trading day?
The percentage price change of RAPPORT THERAPEUTICS INC (RAPP:NASDAQ) since the previous trading day is -0.5037%.
What is the most recent average sentiment score for RAPPORT THERAPEUTICS INC (RAPP:NASDAQ)?
The most recent average sentiment score for RAPPORT THERAPEUTICS INC (RAPP:NASDAQ) is 78 out of 100.
What is the most recent average sentiment for RAPPORT THERAPEUTICS INC (RAPP:NASDAQ)?
The most recent sentiment for RAPPORT THERAPEUTICS INC (RAPP:NASDAQ) is .
SEC-8K** Filing Available For RAPPORT THERAPEUTICS INC (RAPP:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.